769195-20-2

Basic information

• Product Name: (3R)-3-[[(1S)-1-carboxamidophenylmethyl]amino]-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
• Synonyms: (3R)-3-[[(1S)-1-carboxamidophenylmethyl]amino]-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
• CAS NO: 769195-20-2
• Molecular Weight: 540.468
• Mol File: 769195-20-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 698.3±65.0 °C(Predicted)
• Density: 1.52±0.1 g/cm3(Predicted)
• CAS DataBase Reference: (3R)-3-[[(1S)-1-carboxamidophenylmethyl]amino]-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: (3R)-3-[[(1S)-1-carboxamidophenylmethyl]amino]-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one(769195-20-2)
• EPA Substance Registry System: (3R)-3-[[(1S)-1-carboxamidophenylmethyl]amino]-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one(769195-20-2)

Safety Data

• Hazardous Substances Data: 769195-20-2(Hazardous Substances Data)

Usage

Description

(3R)-3-[[(1S)-1-carboxamidophenylmethyl]amino]-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one is a complex chiral molecule that features a combination of various functional groups, including an amine, carboxamide, trifluoromethyl, triazolopyrazin, and trifluorophenyl. It has a stereocenter at the 3rd carbon and is composed of a butanone chain attached to a phenylmethylamino group and a triazolopyrazin ring system. (3R)-3-[[(1S)-1-carboxamidophenylmethyl]amino]-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one may have potential pharmaceutical or research applications, but its specific properties and uses would require further investigation and testing.

Uses

Used in Pharmaceutical Industry:
(3R)-3-[[(1S)-1-carboxamidophenylmethyl]amino]-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one is used as a potential pharmaceutical candidate for the development of new drugs due to its complex structure and the presence of various functional groups that may exhibit biological activity.
Used in Research Applications:
In the field of chemical research, (3R)-3-[[(1S)-1-carboxamidophenylmethyl]amino]-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one can be utilized as a subject for studying the synthesis, properties, and potential applications of complex chiral molecules. Its unique structure may provide insights into the design and development of new compounds with specific functions and activities.

Upstream product

• 209995-38-0 (2,4,5-trifluorophenyl)acetic acid 
• 6485-52-5 L-phenylglycine amide 
• 764667-65-4 1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butane-1,3-dione 
• 486460-21-3 3-trifluoromethyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine 
• 769195-19-9 (2S)-2({(1Z)-3-oxo-1-(2,4,5-trifluorobenzyl)-3-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-]pyrazin-7(8H)-yl]prop-1-enyl}amino-2-phenylethanamide) 
• 1253056-01-7 (R/S)-3-hydroxy-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one 
• 1253056-18-6 C₁₆H₁₂F₆N₄O 

Downstream Products

• 654671-78-0 sitagliptin phosphate 
• 486460-32-6 sitagliptin 
• 823817-55-6 (S)-Sitagliptin 

Relevant articles and documents

A west he row sandbank and intermediate preparation method

The invention relates to the field of medicament synthesis and especially relates to a preparation method of sitagliptin and an intermediate thereof. The preparation method of a compound show as formula III is as below: in the presence of a first organic solvent, a compound shown as formula I and a compound shown as formula II conduct reductive amination reaction under the action of a reducing agent and organic acid, so as to obtain the compound shown in formula III. The preparation method provided by the invention does not use precious metal as the catalyst, reduces the cost, simplifies the synthesis process, increases the yield, and improves the chemical purity and optical purity of sitagliptin. R represents methyl or carbamyl, and Ar represents phenyl, monosubstituted phenyl or polysubstituted phenyl.

Synthesis of sitagliptin phosphate by a NaBH4/ZnCl2-catalyzed diastereoselective reduction

A practical asymmetric synthesis of sitagliptin phosphate, from 1-{3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo-[4,3-a]pyrazin-7(8H)-yl}-4-(2,4,5-trifluorophenyl) butane-1,3-dione, in overall 65.3% yield has been reported. The target compound was synth

Practical and economical approach to synthesize sitagliptin

Economic syntheses of sitagliptin phosphate monohydrate, acknowledged as the first dipeptidyl peptidase 4 (DPP-4) inhibitor, have been achieved in an overall yield of 42.4% in four steps from 1-{3-(trifluoromethyl)-5,6-dihydro-[1, 2,4]triazolo[4,3-a]pyrazin-7(8H)-yl}-4-(2,4,5-trifluorophenyl)butane-1,3-dione. The key stereoselective reduction of this process was carried out by NaBH 4/HCOOH instead of expensive and toxic catalysts or ligands. [Supplementary materials are available for this article. Go to the publisher's online edition of Synthetic Communications for the following free supplemental resource(s): Full experimental and spectral details.]